| abstract |
Claim 1: A pharmaceutical composition characterized in that it comprises or is made of a DPP4 inhibitor, an accompanying drug, one or more pharmaceutical excipients and a nucleophilic and / or basic agent for stabilizing said DPP4 inhibitor against degradation. Claim 4: The pharmaceutical composition according to any one of claims 1 2 or 3, characterized in that the accompanying drug is selected from the group consisting of biguanides such as metformin hydrochloride, thiazolidinones as pioglitazone hydrochloride, statins such as atorvastatin, and BRA as telmisartan. Claim 5: The pharmaceutical composition according to any one of claims 1 to 4, characterized in that the nucleophilic and / or basic agent or the buffering substance is a basic amino acid having an intramolecular amino group and alkaline characteristics, including L-arginine, L -lisin and L-histidine, Claim 7: The pharmaceutical composition according to any one of claims 1 to 6, characterized in that the DPP4 inhibitor is selected from vildagliptin, saxagliptin and alogliptin. Claim 8: The pharmaceutical composition according to any one of claims 1 to 6, characterized in that the DPP4 inhibitor is the free base of 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl- 7- (2-Butin-1-yl) -8- (3- (R) -amino-piperidin-1-yl) -xanthine. |